Compare Dollar General Corp. (DG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Vertex Pharmaceuticals Incorporated — how do they compare? Dollar General Corp. trades at $124.27 (market cap $27.42B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.7× Dollar General Corp.'s market cap, and Dollar General Corp. pays a 1.9% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| DG | VRTX | |
|---|---|---|
Market Cap | $27.42B | $128.16B |
Volume | 2,291,517 | 806,603 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $557.96 |
52-Week Low | $95.94 | $407.37 |
Typical Hold Time | 59 Days | 120 Days |
Enterprise Value | $41.60B | $122.29B |
Dividend Yield | 1.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DG trades at $122.16, down 0.89% on the day, with a neutral technical signal. The stock shows strong profitability with a 19.69% ROE and has beaten earnings estimates for the last three quarters. Recent news highlights margin benefits from tariff refunds and expansion of delivery services through Instacart. Cash flow from operations improved to $3.0 billion in 2025, supporting financial stability.
The outlook is positive with a consensus price target of $137.27, implying over 12% upside. Risks include competitive pressures and potential consumer spending weakness. Analyst sentiment is bullish with 55.77% buy ratings, but net income margin compression from 7.01% in 2022 to 2.77% in 2025 warrants monitoring.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
